Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peplinski, G. R.
Right arrow Articles by Norton, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peplinski, G. R.
Right arrow Articles by Norton, J. A.

Annals of Surgical Oncology, Vol 2, Issue 2 151-159, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta

G. R. Peplinski, K. Tsung, E. D. Whitman, J. B. Meko and J. A. Norton
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

BACKGROUND: Human interleukin-1 beta (hIL-1 beta) injected intratumorally has demonstrated growth inhibition of transplanted subcutaneous tumors in mice, regression of metastatic lesions, resistance to tumor rechallenge, and increased survival. Vaccinia virus (VV) can be genetically engineered to produce cytokines and may be an effective vector for gene therapy of cancer. This study was designed to (a) construct a VV expressing hIL-1 beta, (b) assess tumor cell infection in vitro with this construct, (c) measure hIL-1 beta production, and (d) assess the bioactivity of the secreted cytokine. METHODS: The hIL-1 beta gene was amplified from a plasmid clone using polymerase chain reaction (PCR) and then cloned into a homologous recombination (HR) and expression vector, which was used to insert the hIL-1 beta gene into the VV genome. Selection of the recombinant VV (vMJ601hIL-1 beta) was based on inactivation of viral TK and expression of beta-galactosidase. vMJ601hIL-1 beta infectivity and cytokine production was assessed by infecting tumor cell lines and analyzing culture supernatants for hIL-1 beta. Bioactivity of the hIL-1 beta produced was demonstrated using an IL-1 dependent T helper cell line. RESULTS: The hIL-1 beta gene was successfully cloned into the VV genome by HR, which was confirmed by PCR. vMJ601hIL-1 beta efficiently infected tumor cells, as shown by increased hIL-1 beta secretion (0 to > 500 ng/ml) and morphologic evidence of viral cytopathic effect. vMJ601hIL-1 beta-infected cells secreted large amounts of hIL-1 beta (mean 772 ng/10(6) cells/24 h). The secreted hIL-1 beta was bioactive (mean bioactivity 6.8 x 10(8) U/mg of hIL-1 beta). CONCLUSIONS: (a) hIL-1 beta can be cloned into VV, (b) vMJ601hIL-1 beta retains its infectivity, (c) a large amount of hIL-1 beta is secreted, and (d) the secreted hIL-1 beta is bioactive. Recombinant VV may allow in situ cytokine gene delivery and expression in established tumors.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
W.-H. Shen, J.-H. Zhou, S. R. Broussard, G. G. Freund, R. Dantzer, and K. W. Kelley
Proinflammatory Cytokines Block Growth of Breast Cancer Cells by Impairing Signals from a Growth Factor Receptor
Cancer Res., August 15, 2002; 62(16): 4746 - 4756.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Saijo, M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, et al.
Proinflammatory Cytokine IL-1{beta} Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction
J. Immunol., July 1, 2002; 169(1): 469 - 475.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. F. X. Gnant, L. A. Noll, K. R. Irvine, M. Puhlmann, R. E. Terrill, H. R. Alexander Jr., and D. L. Bartlett
Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases
J Natl Cancer Inst, October 20, 1999; 91(20): 1744 - 1750.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. F. X. Gnant, A. C. Berger, J. Huang, M. Puhlmann, P. C. Wu, M. J. Merino, D. L. Bartlett, H. Richard Alexander, and S. K. Libutti
Sensitization of Tumor Necrosis Factor {{alpha}}-resistant Human Melanoma by Tumor-specific in Vivo Transfer of the Gene Encoding Endothelial Monocyte-activating Polypeptide II Using Recombinant Vaccinia Virus
Cancer Res., September 1, 1999; 59(18): 4668 - 4674.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. F. X. Gnant, M. Puhlmann, H. R. Alexander Jr., and D. L. Bartlett
Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice
Cancer Res., July 1, 1999; 59(14): 3396 - 3403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.